Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2019 09:29 ET | Source: Altimmune, Inc.

Altimmune Announces $14 million Registered Direct Offering

GAITHERSBURG, Md., March 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with two...
January 29, 2019 08:00 ET | Source: Altimmune, Inc.

Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress™ in Vienna, Austria

GAITHERSBURG, Md., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1...
December 13, 2018 07:01 ET | Source: Altimmune, Inc.

Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion

GAITHERSBURG, Md., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical programs and plans to further...
November 30, 2018 18:06 ET | Source: Altimmune, Inc.

Altimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a clinical-stage immunotherapeutics company, granted equity awards on November 30, 2018, that were previously...
November 27, 2018 09:00 ET | Source: Altimmune, Inc.

Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer

GAITHERSBURG, Md., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Garg, Ph.D. as its...
November 13, 2018 16:50 ET | Source: Altimmune, Inc.

Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update

GAITHERSBURG, Md., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three and nine months ended...
October 26, 2018 11:29 ET | Source: Altimmune, Inc.

Altimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference

GAITHERSBURG, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive...
October 08, 2018 09:00 ET | Source: Altimmune, Inc.

Altimmune Announces $25 million Registered Direct Offering

GAITHERSBURG, Md., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with several...
October 03, 2018 08:00 ET | Source: Altimmune, Inc.

Altimmune Closes on $16.9 Million in Funding

$12 million underwritten public offering closed October 2$4.9 million registered direct offering closed September 26 GAITHERSBURG, Md., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:...
September 28, 2018 09:01 ET | Source: Altimmune, Inc.

Altimmune Announces Pricing of $12 Million Underwritten Public Offering

GAITHERSBURG, Md., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the pricing of an underwritten public offering of...